丨 2024年11月22日 星期五 丨NO.1基于癌症和炎症药物乐观前景 诺华制药上调中期销售预期11月21日,基于对新的癌症和免疫疾病药物以及神经和心血管疾病治疗药物的乐观预期,诺华制药上调了中期销售预期。诺华制药表示,到2029年,公司营收将以每年6%的速度增长,高于此前5%的预期。诺华上调了对其旗下药物Cosentyx、Kisqali、Kesimpta、Pluvicto和Leqvio的峰值...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.